Kranus Health raises $6.5M for digital men’s health
Summary
The Munich and Berlin-based company provides holistic treatment of erectile dysfunction with the Kranus Edera app being the first fully reimbursable therapy in urology officially approved by the German Federal Institute for Drugs and Medical Devices**. With Kranus Edera, the company has brought the first digital health application to the market as a fully reimbursable app on prescription for treating erection problems and their causes. Karista is recognized as tier-1 expert in HealthTech, being the first institutional investor of 3 NASDAQ-listed companies as well as in Europes Digital Health pioneer Voluntis (now part of AptarGroup), and supporting several breakthrough products from inception to global markets. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF has also successfully sold interests in more than 150 companies.Investors in this public-private partnership include the Federal Ministry for Economic Affairs and Climate Action, KfW Capital, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, B\xdcFA, CEWE, Deutsche Bank, Deutsche Post DHL, Dr\xe4ger, 1+1 AG, EVONIK, EWE AG, FOND OF, Haniel, Hettich, Knauf, K\xf6rber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Th\xfcga, Vector Informatik, WACKER and Wilh.